OPKO Health, Inc. Current Liabilities
OPKO Health, Inc. (OPK) had Current Liabilities of $149.37 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-28
- 2026-06-30: Liabilities, Current $149.37M.
- 2026-03-31: Liabilities, Current $148.38M.
- 2025-12-31: Liabilities, Current $146.68M.
- 2025-09-30: Liabilities, Current $169.32M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $149.37M 10-Q/A · filed 2026-08-28 | |
| 2026-03-31 | $148.38M 10-Q/A · filed 2026-08-28 | |
| 2025-12-31 | $146.68M 10-Q/A · filed 2026-08-28 | |
| 2025-09-30 | $169.32M 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $171.18M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $295.85M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $193.10M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $211.66M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $219.55M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $204.34M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $200.05M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $200.55M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $226.45M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $222.42M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $213.48M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $267.27M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $215.47M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $309.17M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $330.01M 10-K · filed 2023-02-27 | |
| 2021-09-30 | $283.04M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $303.98M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $403.93M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $375.48M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $335.89M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $279.54M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $245.09M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $249.12M 10-K · filed 2021-02-18 | |
| 2019-09-30 | $270.14M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $283.37M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $396.06M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $288.32M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $317.83M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $306.86M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $318.08M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $312.03M 10-K · filed 2019-03-01 | $301.33M 10-K · filed 2018-03-01 |
| 2017-09-30 | $258.95M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $283.05M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $264.95M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $240.02M 8-K · filed 2019-01-29 | $263.30M 10-K · filed 2017-03-01 |
| 2016-09-30 | $254.51M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $281.24M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $267.23M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $251.90M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $357.59M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $180.48M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $182.84M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $83.11M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $76.84M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $79.40M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $84.50M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $91.85M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $71.38M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $59.47M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $58.22M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $52.38M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $46.44M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $31.71M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $29.70M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $18.78M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $20.24M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $21.53M 10-Q · filed 2011-08-08 | |
| 2010-12-31 | $27.60M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |